DR.YOHIDHA BALAMURUGAN,DR.SUBASH MOHAN,DR.ANANTHAKUMAR. P.K,DR. S. MANIKANDAN
DOI: https://doi.org/The sulfur-containing amino acid called homocysteine is created as a byproduct of the metabolism of methionine. 5 to 15 micromoles per liter (μmol/L) is the normal range for plasma homocysteine levels. Three levels of increased homocysteine are classified either moderate (12–30 μmol/L), medium (31–100 μmol/L), as well as severe (>100 μmol/L) hyperhomocysteinemia. A higher risk of cardiovascular conditions, such as atherosclerosis, stroke, especially coronary heart disease, is linked to elevated homocysteine levels. artery disease, due to mechanisms involving oxidative stress, endothelial dysfunction, & thrombogenesis.
Addition to arterial vascular diseases, hyperhomocysteinemia is a recognized but underdiagnosed risk factor for venous thromboembolism(VTE) encompassing conditions such as deep vein thrombosis (DVT) & pulmonary embolism (PE). This case report describes a young male with no prior medical history who presented with DVT and PE. Subsequent investigations revealed hyperhomocysteinemia as the underlying etiology. The patient was managed with anticoagulants and vitamin supplementation, leading to clinical improvement. This case highlights the importance of identifying and addressing hyperhomocysteinemia among the individuals who have been diagnosed thromboembolic events which reduce hazard recurrence along with long-term complications.
